Stay updated with breaking news from Iontech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BioNTech and Pfizer have received a positive opinion from The Committee for Medicinal Products for Human Use (CHMP) for their updated COVID-19 vaccine, as a single dose for individuals 5 years of age and older, regardless of prior vaccination history, in the EU.
With the rise of mRNA-based treatments, the field of oncology is about to go through a significant change.
The European Commission has authorised an updated COVID-19 vaccine from Pfizer and its German partner BioNtech to be used in EU countries' vaccination campaigns this autumn to target the dominant Omicron XBB.1.5 variant, it said on Friday. The Commission authorises its use for adults, children and infants above six months. The European Medicines Authority (EMA) approved the vaccine earlier this week.
The antibody-drug conjugate will be pitted against chemotherapy in a heavily treated breast cancer subpopulation, with hopes of challenging AstraZeneca and Daiichi Sankyo’s blockbuster Enhertu.
Key Insights The considerable ownership by private equity firms in BioNTech indicates that they collectively have a...